Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank Roesch

Showing results (31-40 of 65) with videos related to

Pageof 7
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|November 6, 2023
Therapeutic potential of [<sup>177</sup>Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessmentMadhav P Yadav, Sanjana Ballal, Marcel Martin, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2025
Efficacy and Safety of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Therapy in Patients with SarcomaSanjana Ballal, Mohammad Sakir, Kunal R Chandekar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 27, 2016
Evaluation of bone-seeking novel radiotracer <sup>68</sup>Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breastAverilicia Passah, Madhavi Tripathi, Sanjana Ballal, et al.
Nuklearmedizin. Nuclear Medicine|April 29, 2020
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinomaBarbara Kreppel, Florian Christoph Gaertner, Hojjat Ahmadzadehfar, et al.
Neuropsychobiology|February 10, 2011
P-glycoprotein influence on the brain uptake of a 5-HT(2A) ligand: [(18)F]MH.MZUlrich Schmitt, Dianne E Lee, Matthias M Herth, et al.
Molecular Pharmaceutics|April 17, 2023
Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>-Mediated Radiotherapy in Triple-Negative Breast CancerGuangfa Bao, Huimin Zhou, Sijuan Zou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 13, 2020
A theranostic approach of [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi PET/CT-guided [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapySanjana Ballal, Madhav Prasad Yadav, Vasko Kramer, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2024
Head-to-Head Comparison of SSTR Antagonist [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4 with SSTR Agonist [<sup>68</sup>Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging StudyRahul Viswanathan, Sanjana Ballal, Madhav P Yadav, et al.
Diagnostics (Basel, Switzerland)|September 28, 2024
[<sup>68</sup>Ga]Ga-DOTAGA-Glu(FAPi)<sub>2</sub> Shows Enhanced Tumor Uptake and Theranostic Potential in Preclinical PET ImagingJulie van Krimpen Mortensen, Simona Mattiussi, Lars Hvass, et al.
Pageof 7

Showing results (31-40 of 65) with videos related to

Sort By:
Pageof 7
European Journal of Nuclear Medicine and Molecular Imaging|November 6, 2023
Therapeutic potential of [<sup>177</sup>Lu]Lu-DOTAGA-FAPi dimers in metastatic breast cancer patients with limited treatment options: efficacy and safety assessmentMadhav P Yadav, Sanjana Ballal, Marcel Martin, et al.
Annals of Nuclear Medicine|March 17, 2019
Preliminary results of biodistribution and dosimetric analysis of [<sup>68</sup>Ga]Ga-DOTA<sup>ZOL</sup>: a new zoledronate-based bisphosphonate for PET/CT diagnosis of bone diseasesAmbreen Khawar, Elisabeth Eppard, Frank Roesch, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 21, 2025
Efficacy and Safety of [<sup>177</sup>Lu]Lu-DOTAGA.Glu.(FAPi)<sub>2</sub> Therapy in Patients with SarcomaSanjana Ballal, Mohammad Sakir, Kunal R Chandekar, et al.
European Journal of Nuclear Medicine and Molecular Imaging|July 27, 2016
Evaluation of bone-seeking novel radiotracer <sup>68</sup>Ga-NO2AP-Bisphosphonate for the detection of skeletal metastases in carcinoma breastAverilicia Passah, Madhavi Tripathi, Sanjana Ballal, et al.
Nuklearmedizin. Nuclear Medicine|April 29, 2020
[177Lu]Lu-DOTA-zoledronate therapy - first application in a patient with primary osseous metastatic bronchial carcinomaBarbara Kreppel, Florian Christoph Gaertner, Hojjat Ahmadzadehfar, et al.
Neuropsychobiology|February 10, 2011
P-glycoprotein influence on the brain uptake of a 5-HT(2A) ligand: [(18)F]MH.MZUlrich Schmitt, Dianne E Lee, Matthias M Herth, et al.
Molecular Pharmaceutics|April 17, 2023
Inhibition of Poly(ADP-ribose) Polymerase Sensitizes [<sup>177</sup>Lu]Lu-DOTAGA.(SA.FAPi)<sub>2</sub>-Mediated Radiotherapy in Triple-Negative Breast CancerGuangfa Bao, Huimin Zhou, Sijuan Zou, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 13, 2020
A theranostic approach of [<sup>68</sup>Ga]Ga-DOTA.SA.FAPi PET/CT-guided [<sup>177</sup>Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapySanjana Ballal, Madhav Prasad Yadav, Vasko Kramer, et al.
Pharmaceuticals (Basel, Switzerland)|March 28, 2024
Head-to-Head Comparison of SSTR Antagonist [<sup>68</sup>Ga]Ga-DATA<sup>5m</sup>-LM4 with SSTR Agonist [<sup>68</sup>Ga]Ga-DOTANOC PET/CT in Patients with Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors: A Prospective Imaging StudyRahul Viswanathan, Sanjana Ballal, Madhav P Yadav, et al.
Diagnostics (Basel, Switzerland)|September 28, 2024
[<sup>68</sup>Ga]Ga-DOTAGA-Glu(FAPi)<sub>2</sub> Shows Enhanced Tumor Uptake and Theranostic Potential in Preclinical PET ImagingJulie van Krimpen Mortensen, Simona Mattiussi, Lars Hvass, et al.
Pageof 7